CD6 immunotherapy to treat psoriasis and rheumatoid arthritis has reached the clinical trial
stage with apparent success, and targeting CD6 with mAbs is being used in several animal …

The great majority of mammalian genes yield multiple transcripts arising from differential
mRNA processing, but in very few instances have alternative forms been assigned distinct …

Human Vγ9Vδ2 T cells, a major innate-like peripheral T cell subset, are thought to play in
vivo a key role in innate and adaptive immune responses to infection agents and tumors …

CD25 has become widely used as a marker for a subset of regulatory CD4+ T cells present
in the thymus and periphery of mice, rats and humans. However, CD25 is also expressed on …

The cell surface receptor CD6 regulates T cell activation in both activating and inhibitory
manners. The adaptor protein SLP-76 is recruited to the phosphorylated CD6 cytoplasmic …

CD6 is a cell surface receptor primarily expressed on immature thymocytes and mature T
and B1a lymphocytes. Through its binding to activated leukocyte cell adhesion molecule …

Triggering of the T cell receptor initiates a signaling cascade resulting in the activation of the
T cell. These signals are integrated alongside those resulting from the triggering of other …

CD6 is a 105–130 kDa surface glycoprotein expressed on the majority of T cells and a
subset of B cells. The human cd6 gene maps to chromosome 11, and the expression of its …

We previously reported that human Vγ2Vδ2-γδT cells were activated by many human tumor
cell lines treated with pamidronate (PAM) in a γδTCR-dependent manner. In the present …

The transmembrane surface glycoprotein CD6 was one of the first antigens identified on T
lymphocytes. The recognition of its involvement in T-cell signaling processes heralds the …